Loading stock data…
United Therapeutics Corporation (UTHR)
$528.47-1.06 (-0.20%)
Market ClosedLast close Jul 24
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
United Therapeutics Corporation in the Healthcare sector is trading at $528.47 with a market capitalization of $23.3B. Wall Street consensus targets $663.23 (13 analysts), implying a +25.5% move over the next 12 months. The stock is currently 13% below its 52-week high of $609.35, remaining 3.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $781.50M↓ | $790.20M↓ | $799.50M↑ | $798.60M↑ | $794.40M |
| Gross Profit | $648.10M↓ | $686.80M↓ | $698.60M↓ | $711.00M↑ | $701.90M |
| Operating Income | $325.80M↓ | $357.50M↓ | $389.30M↑ | $386.20M↑ | $382.80M |
| Net Income | $274.90M↓ | $364.30M↑ | $338.70M↑ | $309.50M↓ | $322.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.82%
Volume
Today's trading volume
290,257
Recent News
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
Liquidia is expanding the use of its pulmonary hypertension drug YUTREPIA into additional indications after early commercial traction. Ongoing patent litigation with United Therapeutics has moved in a direction that appears favorable for Liquidia, with a delayed ruling reducing the risk that YUTREPIA is removed from the market. These developments could affect the opportunity for NasdaqCM:LQDA shareholders by influencing the size and durability of YUTREPIA's addressable market. Liquidia...
United Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong Returns
United Therapeutics stock has delivered a strong compound return of 195.7% over the past 5 years, yet the company still screens as undervalued on several valuation checks, which raises the question of how much of its recent progress the share price already reflects. A 195.7% return over 5 years suggests United Therapeutics has already rewarded patient shareholders. Fresh buyers need to think carefully about how much future upside is still priced in. Recent developments in transplant and...
BETA Technologies (BETA), Multistate Collaborative Complete Inaugural eVTOL Integration Pilot Program Flights
BETA Technologies Inc. (NYSE:BETA) is one of the stocks set to explode in the next 2 years. On July 10, BETA Technologies and the Multistate Collaborative completed the first flights under the US DOT and FAA’s eVTOL Integration Pilot Program. These inaugural missions, which spanned a corridor between Virginia and Maryland, successfully utilized electric aircraft […]